Literature DB >> 28760489

MDR in cancer: Addressing the underlying cellular alterations with the use of nanocarriers.

Manu S Singh1, Salma N Tammam2, Maryam A Shetab Boushehri1, Alf Lamprecht3.   

Abstract

Multidrug resistance (MDR) is associated with a wide range of pathological changes at different cellular and intracellular levels. Nanoparticles (NPs) have been extensively exploited as the carriers of MDR reversing payloads to resistant tumor cells. However, when properly formulated in terms of chemical composition and physicochemical properties, NPs can serve as beyond delivery systems and help overcome MDR even without carrying a load of chemosensitizers or MDR reversing molecular cargos. Whether serving as drug carriers or beyond, a wise design of the nanoparticulate systems to overcome the cellular and intracellular alterations underlying the resistance is imperative. Within the current review, we will initially discuss the cellular changes occurring in resistant cells and how such changes lead to chemotherapy failure and cancer cell survival. We will then focus on different mechanisms through which nanosystems with appropriate chemical composition and physicochemical properties can serve as MDR reversing units at different cellular and intracellular levels according to the changes that underlie the resistance. Finally, we will conclude by discussing logical grounds for a wise and rational design of MDR reversing nanoparticulate systems to improve the cancer therapeutic approaches.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Multidrug resistance (MDR); Nanoparticles (NP)

Mesh:

Substances:

Year:  2017        PMID: 28760489     DOI: 10.1016/j.phrs.2017.07.023

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

1.  Synergistic antitumor efficacy of PD-1-conjugated PTX- and ZSQ-loaded nanoliposomes against multidrug-resistant liver cancers.

Authors:  Mingjia Gu; Fang Yin; Yuening Qin; Yali Tian; Xinjie Xiu; Hanjing Shen; Jiebin Zhu
Journal:  Drug Deliv Transl Res       Date:  2022-01-15       Impact factor: 5.671

2.  P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Authors:  Chengqiong Mao; Yan Zhao; Fang Li; Zibo Li; Shaomin Tian; Waldemar Debinski; Xin Ming
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

3.  Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles.

Authors:  Sara Zalba; Ann L B Seynhaeve; Jos F Brouwers; Regine Süss; Marcel Verheij; Timo L M Ten Hagen
Journal:  Nanoscale       Date:  2020-08-11       Impact factor: 7.790

4.  pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization.

Authors:  Vincent Pautu; Elise Lepeltier; Adélie Mellinger; Jérémie Riou; Antoine Debuigne; Christine Jérôme; Nicolas Clere; Catherine Passirani
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 5.  Functionalized Carbon Nanostructures Versus Drug Resistance: Promising Scenarios in Cancer Treatment.

Authors:  Manuela Curcio; Annafranca Farfalla; Federica Saletta; Emanuele Valli; Elvira Pantuso; Fiore Pasquale Nicoletta; Francesca Iemma; Orazio Vittorio; Giuseppe Cirillo
Journal:  Molecules       Date:  2020-04-30       Impact factor: 4.411

6.  Enhanced anticancer activity and intracellular uptake of paclitaxel-containing solid lipid nanoparticles in multidrug-resistant breast cancer cells.

Authors:  Wenting Xu; Eun Ju Bae; Mi-Kyung Lee
Journal:  Int J Nanomedicine       Date:  2018-11-15

7.  Arminin 1a-C, a novel antimicrobial peptide from ancient metazoan Hydra, shows potent antileukemia activity against drug-sensitive and drug-resistant leukemia cells.

Authors:  Xiaolei Liang; Ruirui Wang; Wenshan Dou; Li Zhao; Lanxia Zhou; Junfang Zhu; Kairong Wang; Jiexi Yan
Journal:  Drug Des Devel Ther       Date:  2018-10-31       Impact factor: 4.162

Review 8.  Engineered Polymeric Materials for Biological Applications: Overcoming Challenges of the Bio-Nano Interface.

Authors:  Joshua D Simpson; Samuel A Smith; Kristofer J Thurecht; Georgina Such
Journal:  Polymers (Basel)       Date:  2019-09-02       Impact factor: 4.329

9.  Mitochondria-targeted delivery of doxorubicin to enhance antitumor activity with HER-2 peptide-mediated multifunctional pH-sensitive DQAsomes.

Authors:  Menghao Shi; Jiulong Zhang; Xiaowei Li; Shuang Pan; Jie Li; Chunrong Yang; Haiyang Hu; Mingxi Qiao; Dawei Chen; Xiuli Zhao
Journal:  Int J Nanomedicine       Date:  2018-07-18

10.  Synthesis and antitumor activity of novel pyridinium fullerene derivatives.

Authors:  Takumi Yasuno; Tomoyuki Ohe; Hitomi Ikeda; Kyoko Takahashi; Shigeo Nakamura; Tadahiko Mashino
Journal:  Int J Nanomedicine       Date:  2019-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.